Delhi High Court has granted an interim injunction against Zydus Lifesciences over the company’s proposed nivolumab product | ...

If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article ...

Experts from Dechert, BlueRock Therapeutics, Merck, Seaport Therapeutics, and Ventus Therapeutics examine the impact of ...

31 March 2025 With billions in revenue at stake, the pharma giant has a 27-country parallel litigation effort to protect its ...

The Arusha Protocol is a catalyst for agricultural transformation. It provides legal assurance and financial incentives for ...

To request a FREE 2-week trial subscription, please signup. NOTE - this can take up to 48hrs to be approved.

This LSPN panel features experts from Maiwald, Regeneron, Vertex Pharmaceuticals, and Taylor Wessing discussing the impact of ...

After almost 30 years as head of IP at Bayer, Jörg Thomaier is to retire and is handing the baton to Dorian Immler. Speaking ...

Disputed drug forms part of a multi-billion dollar franchise for J&J, ranking among its largest revenue drivers in mental ...

4 February 2025 LSIPR sister title WIPR releases USA Patents Rankings, divided into categories of non-contentious and ...

LSPN panellists from Mathys & Squire discuss recent developments affecting the EPO Boards of Appeal and decisions emerging ...

Non-profit alleges that Humira pricing displaced essential healthcare, violated EU competition law and breached human rights | Court notes ‘social significance’ of case—but this can’t translate into ...